Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 2,253 call options on the company. This is an increase of 533% compared to the typical volume of 356 call options.
Wave Life Sciences Stock Up 74.1 %
NASDAQ WVE opened at $14.90 on Thursday. The company has a market capitalization of $1.82 billion, a PE ratio of -28.65 and a beta of -1.10. Wave Life Sciences has a 12-month low of $3.50 and a 12-month high of $15.54. The firm’s 50 day moving average is $6.72 and its 200-day moving average is $6.10.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.09). The business had revenue of $19.69 million for the quarter, compared to the consensus estimate of $24.80 million. Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. During the same period last year, the firm earned ($0.20) earnings per share. As a group, sell-side analysts expect that Wave Life Sciences will post -1.02 EPS for the current year.
Insider Activity at Wave Life Sciences
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Wave Life Sciences during the fourth quarter worth $174,000. Wellington Management Group LLP raised its holdings in shares of Wave Life Sciences by 3.5% in the 4th quarter. Wellington Management Group LLP now owns 274,093 shares of the company’s stock valued at $1,384,000 after purchasing an additional 9,208 shares during the period. Capstone Investment Advisors LLC lifted its stake in Wave Life Sciences by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 54,500 shares of the company’s stock valued at $336,000 after purchasing an additional 4,500 shares during the last quarter. GSA Capital Partners LLP bought a new position in Wave Life Sciences during the first quarter worth about $586,000. Finally, Swiss National Bank increased its position in Wave Life Sciences by 2.7% during the first quarter. Swiss National Bank now owns 156,500 shares of the company’s stock worth $966,000 after buying an additional 4,100 shares during the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
WVE has been the subject of a number of recent analyst reports. Raymond James raised Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $13.00 to $22.00 in a research note on Wednesday. HC Wainwright increased their target price on shares of Wave Life Sciences from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Wells Fargo & Company lifted their price target on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday. Mizuho restated an “outperform” rating and set a $19.00 target price on shares of Wave Life Sciences in a report on Tuesday, June 25th. Finally, B. Riley upped their price target on shares of Wave Life Sciences from $11.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.11.
Read Our Latest Research Report on WVE
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
See Also
- Five stocks we like better than Wave Life Sciences
- Compound Interest and Why It Matters When Investing
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Do ETFs Pay Dividends? What You Need to Know
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What Are Trending Stocks? Trending Stocks Explained
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.